Eptifibatide

Eptifibatide is a synthetic cyclic heptapeptide that acts as a potent, reversible inhibitor of the platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor, the final common pathway of platelet aggregation. The drug was designed based on the structure of barbourin, a disintegrin peptide found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). The key pharmacophore is a KGD (lysine-glycine-aspartate) sequence that mimics the RGD (arginine-glycine-aspartate) recognition motif used by fibrinogen to cross-link activated platelets.

GP IIb/IIIa is the most abundant receptor on the platelet surface, with approximately 80,000 copies per platelet. When platelets are activated, GP IIb/IIIa undergoes a conformational change that exposes binding sites for fibrinogen and von Willebrand factor, allowing these proteins to bridge adjacent platelets and form a platelet thrombus. By competitively blocking these binding sites, eptifibatide prevents platelet cross-linking and thrombus formation.

Eptifibatide is used intravenously in the acute management of unstable angina and non-ST-elevation myocardial infarction (NSTEMI), and as an adjunct to percutaneous coronary intervention (PCI). The PURSUIT trial demonstrated a significant reduction in the composite endpoint of death or myocardial infarction with eptifibatide in patients with acute coronary syndromes. The ESPRIT trial showed benefit when used during PCI with coronary stenting.

As an intravenous agent with rapid onset and short duration of action (platelet function recovers within 4-8 hours after discontinuation), eptifibatide offers the advantage of controllable antiplatelet effect in the acute setting. This reversibility is clinically important for patients who may require urgent surgery, where longer-acting antiplatelet agents would increase bleeding risk.